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Key Clinical Message
We report here a patient with extremely indolent mantle cell lymphoma (MCL)
who had progressed and required immunochemotherapy 20 years after diagnos-
tic splenectomy. Non-nodal, indolent MCL patients may progress after such an
extraordinary long indolent phase, and we recommend lifelong follow up for
such cases.
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Splenectomy
Mantle cell lymphoma (MCL) is a distinct subtype of B-cell
neoplasms characterized by t(11;14)(q13;q32), which leads
to constitutive deregulation of cyclin D1. Patients are
typically diagnosed at over 60 years of age and have
advanced-stage disease. They are incurable with standard
chemotherapy and exhibit an unfavorable clinical course
with a median overall survival of 4–5 years. We report here
a patient with splenic MCL who followed an extremely
indolent clinical course. After long-term remission follow-
ing splenectomy, the patient finally progressed and received
first immunochemotherapy 20 years after initial diagnosis.
A 48-year-old, previously healthy female was found to
have an enlarged spleen without any symptoms and
received diagnostic splenectomy in 1995. Histological
examination revealed a monotonous proliferation of
small-to-medium sized cleaved B cells in the white pulp,
with weak CD5 and cyclin D1 expression. These B cells
were shown to be positive for IgMk by flow cytometry,
and positive for t(11;14) by chromosomal analysis.
According to these results, the patient was diagnosed with
splenic MCL (Fig. 1A). Peripheral lymphocyte count was
4000/lL and contained 20% of IgMk B cells at presenta-
tion, but this cell population became undetectable after
splenectomy. Because no other mass lesions were detected
and only minimal involvement was found in the bone
marrow, the patient was observed without additional
treatment.
She had long been asymptomatic, but developed dry
cough after 18 years’ remission following splenectomy.
18F-fluoro-2-deoxy-D-glucose positron emission tomogra-
phy and computed tomography (FDG-PET/CT) scan
found her lymphoma progressed at hilar lymph nodes,
along with an increase in serum sIL-2 receptor (Fig. 2A).
Screening upper and lower endoscopic examination found
slight elevation of the mucosa with a rough texture in the
duodenum and ascending to transverse colon, and lym-
phoma involvement was confirmed by the biopsies of
these lesions (Fig. 1B).
Flow cytometry detected 5% CD5+ IgMk+ B cells in the
bone marrow. Chromosomal analysis failed to detect the
karyotype of the tumor cells, but fluorescence in situ
hybridization (FISH) demonstrated that these tumor cells
were positive for t(11;14) and negative for 17p deletion.
Twenty years after splenectomy, she eventually received
six cycles of R-CVP therapy at the age of 68 and has been
in complete remission for 7 months.
We examined the t(11;14) break point junctions by
long-distance polymerase chain reaction (PCR) [1] and
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Figure 1. Histological images of lymphoma samples from the (A) spleen and (B) duodenum stained with (a, b) hematoxylin and eosin, (c) CD20
(L26; DAKO, Carpinteria, CA), (d) CD5 (4C7; Leica, Wetzler, Germany), (e) cyclin D1 (SP4-R; Roche, Mannheim, Germany), (f) Sox11 (polyclonal,


























































































Figure 2. (A) Changes in serum sIL-2R levels of the patient (normal range: 145–519 U/mL). (B) Results of PCR analysis for the detection of t
(11;14) (forward primer: 50-CTCTTTATCTGAGTGGGATGAGA-30; reverse primer: 50-ACCTGAGGAGACGGTGACCAGGGT-30). As a negative
control, genomic DNA from a healthy volunteer was used. Sequence alignment of the translocation break point junction is shown (common to all
samples). (C) SHM analysis of the IGH variable region of the tumor cells. The tumor-specific IGH variable region was PCR amplified (forward
primer: 50-AGTGGGAGCACCAACTACAACCCCTCCC-30; reverse primer: 50-TAGTCAATCGTCCCCGGGGTGCCG-30), and SHM was analyzed by
sequencing of the PCR products. CDR, complementarity-determining region; FR, framework region.
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Sanger sequencing of bone marrow-derived genomic
DNA samples extracted by the phenol–chloroform
method. Then, we created tumor-specific PCR primers
for the detection of t(11;14) in DNA extracted from for-
malin-fixed, paraffin-embedded (FFPE) tumor samples
using NucleoSpin DNA FFPE XS (Macherey-Nagel,
Duren, Germany). Sequence analysis of the PCR products
showed that all the tumor cells from the spleen and those
from the bone marrow, duodenum, and colon at progres-
sion carried the same t(11;14) junctional sequence
(Fig. 2B), suggesting that they were clonally identical.
We next determined the tumor-specific VDJ sequence
of the IGH gene by semi-nested PCR [2] using bone
marrow-derived DNA and created new PCR primers for
the detection of the tumor-specific VDJ sequence in
FFPE-extracted DNA samples. Somatic hypermutation
(SHM) analysis of the PCR products found two muta-
tions common to all samples and three additional muta-
tions in the bone marrow and intestine samples,
indicating that the tumor cells in the bone marrow and
intestine had evolved from preceded splenic tumor cells
(Fig. 2C). In accordance with these results, it was sug-
gested that a minimal MCL clone remained in the
patient following splenectomy, and it eventually evolved
to systemic MCL and required treatment 20 years after
the initial diagnosis.
The clinical course of MCL is usually aggressive, but a
proportion of patients are recognized to have an indolent
clinical course and do not require immediate treatment.
In particular, a distinct subgroup of indolent MCL with a
predominantly leukemic and splenic disease has been rec-
ognized [3]. These non-nodal, indolent MCL cells have
several marked differences from conventional MCL cells,
such as high SHM rate in the IGH gene and low expres-
sion of Sox11 [4, 5]. Palomero et al. have demonstrated
that Sox11 promotes tumor angiogenesis through tran-
scriptional regulation of PDGFA in MCL, and they
hypothesized that non-nodal localization of Sox11-nega-
tive MCL cells may reflect their low angiogenic potential
[6]. They also suggested that Sox11 expression level sepa-
rates MCL into two subtypes of different cell of origin
because Sox11 has a function of repressing BCL6 tran-
scription [7]. Our patient originally had a typical non-
nodal MCL, and it eventually evolved into systemic MCL
after a long period of time. Although the intestine is a
frequently involved site in MCL patients, the intestinal
tumors of the patient were atypical for MCL with weak
Sox11 expression (Fig. 1B), which suggested their evolu-
tion from indolent MCL of a non-nodal type. High SHM
mutation rate in the IGH gene also supported their
derivation from non-nodal MCL.
Because the t(11;14) breakpoint junctions are found
in the variable region of the IGH gene, t(11;14)
translocation is considered to be generated by an error
during VDJ rearrangement in the early B-cell develop-
mental stage, just the same as the t(14;18) transloca-
tion. It has been suggested that t(11;14)-positive clonal
B cells can be detected in healthy individuals at very
low levels, and only a minority of them subse-
quently develop into MCL. However, the natural history
of t(11;14)-positive B cells is only marginally recog-
nized, in contrast to t(14;18)-positive B cells, which
has accumulated evidence for their long-term clonal
persistence. This may be due to the lower frequency of
t(11;14)-positive B cells in healthy individuals compared
with t(14;18)-positive B cells, and the poor outcome of
MCL, which prevents the opportunity for long-term
observation.
Mantle cell lymphoma cells of a non-nodal type are
reported to carry very few chromosomal alterations com-
pared with conventional systemic MCL [5]. Therefore, it
can be speculated that the primary splenic tumor cells of
our patient required decades to acquire additional genetic
abnormalities to evolve into systemic MCL, at the typical
age range for MCL. To the best of our knowledge, this is
the only report demonstrating this length of persistence
of a t(11;14)-positive clone in a MCL patient during
remission. Our report adds an important evidence that
non-nodal MCL patients may progress after such an
extraordinary long indolent phase. According to our
experience, we recommend lifelong follow up for these
patients.
Authorship
YO: performed genetic analysis; MN: drafted the manu-
script; MN, TK, TO and TI: participated in the clinical
care of the patient; HH: performed histological diagnosis:
and ATK: supervised the manuscript.
Conflicts of Interest
The authors have no financial conflict of interests to dis-
close with regard to this report.
References
1. Belaud-Rotureau, M. A., M. Parrens, P. Dubus,
J. C. Garroste, A. de Mascarel, and J. P. Merlio. 2002. A
comparative analysis of FISH, RT-PCR, PCR, and
immunohistochemistry for the diagnosis of mantle cell
lymphomas. Mod. Pathol. 15:517–525.
2. Ramasamy, I., M. Brisco, and A. Morley. 1992. Improved
PCR method for detecting monoclonal immunoglobulin
heavy chain rearrangement in B cell neoplasms. J. Clin.
Pathol. 45:770–775.
480 ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.
Long-term persistence of a t(11;14)-positive clone Y. Otsuka et al.
3. Royo, C., A. Navarro, G. Clot, I. Salaverria, E. Gine,
P. Jares, et al. 2012. Non-nodal type of mantle cell
lymphoma is a specific biological and clinical subgroup of
the disease. Leukemia 26:1895–1898.
4. Navarro, A., G. Clot, C. Royo, P. Jares, A. Hadzidimitriou,
A. Agathangelidis, et al. 2012. Molecular subsets of mantle
cell lymphoma defined by the IGHV mutational status and
SOX11 expression have distinct biologic and clinical
features. Cancer Res. 72:5307–5316.
5. Fernandez, V., O. Salamero, B. Espinet, F. Sole, C. Royo,
A. Navarro, et al. 2010. Genomic and gene expression
profiling defines indolent forms of mantle cell lymphoma.
Cancer Res. 70:1408–1418.
6. Palomero, J., M. C. Vegliante, M. L. Rodriguez, A. Eguileor,
G. Castellano, E. Planas-Rigol, et al. 2014. SOX11 promotes
tumor angiogenesis through transcriptional regulation of
PDGFA in mantle cell lymphoma. Blood 124:2235–2247.
7. Palomero, J., M. C. Vegliante, A. Eguileor, M. L.
Rodriguez, P. Balsas, D. Martinez, et al. 2016. SOX11
defines two different subtypes of mantle cell lymphoma
through transcriptional regulation of BCL6. Leukemia
30:1596–1599.
ª 2017 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. 481
Y. Otsuka et al. Long-term persistence of a t(11;14)-positive clone
